NMF
  • Menu Canvas
    • NMF
      • Nikki Mitchell Foundation
      • Nikki Mitchell
        • Bridge of Wings Flight
        • Documentary
      • Financials and Board
      • Contact Us
    • Programs
      • Bridge of Wings
      • Hope Suite Hope
    • Pancreatic Cancer
      • Statistics & Risk Factors
      • Research & Detection
        • Seed Grant Awardees
    • Inspiration
      • Volunteers
      • Warriors
    • Events
      • Previous Event Photos
    • News
    • Donate
    • NMF
      • Nikki Mitchell Foundation
      • Financials and Board
      • Nikki Mitchell
      • Contact
    • Pancreatic Cancer
      • Statistics & Risk Factors
      • Research & Detection
    • Programs
      • Bridge of Wings
      • Hope Suite Hope
    • Inspiration
      • Warriors
      • Volunteers
    • Events
    • News
NMF
  • NMF
    • Nikki Mitchell Foundation
    • Nikki Mitchell
      • Bridge of Wings Flight
      • Documentary
    • Financials and Board
    • Contact Us
  • Programs
    • Bridge of Wings
    • Hope Suite Hope
  • Pancreatic Cancer
    • Statistics & Risk Factors
    • Research & Detection
      • Seed Grant Awardees
  • Inspiration
    • Volunteers
    • Warriors
  • Events
    • Previous Event Photos
  • News
  • Donate

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Christa Bowles
January 2, 2019
Blog

Article reposted from The New England Journal of Medicine, December 20, 2018.

Abstract

BACKGROUND

Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.

METHODS

We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety.

RESULTS

At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis).

CONCLUSIONS

Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135; EudraCT number, 2011-002026-52.)

Article by: Thierry Conroy, M.D., Pascal Hammel, M.D., Ph.D., Mohamed Hebbar, M.D., Ph.D., Meher Ben Abdelghani, M.D., Alice C. Wei, M.D., C.M., Jean-Luc Raoul, M.D., Ph.D., Laurence Choné, M.D., Eric Francois, M.D., Pascal Artru, M.D., James J. Biagi, M.D., Thierry Lecomte, M.D., Ph.D., Eric Assenat, M.D., Ph.D., for the Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group

Tags: Adjuvant Therapy FOLFIRINOX Gemcitabine pancreatic cancer the new england journal of medicine
Previous Story
NMF Friends Raise $5,000 from Normandy, TN Event
Next Story
After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer

Related Articles

Your Dollars at Work

Nikki Mitchell Foundation is a relatively young non-profit. In the...

2021 Impact Report

2021 was full of challenges for everyone, but the Nikki...

Recent Posts

  • Music Leader Shannan Hatch Joins Nikki Mitchell Foundation Board Wednesday, 30, Mar
  • Your Dollars at Work Thursday, 27, Jan
  • 2021 Impact Report Monday, 24, Jan
  • 2021 Nikki Mitchell Foundation Seed Grant Winner Monday, 22, Nov
  • A Surviving Story Thursday, 17, Jun

Contact Us

1-615-982-6802
PO Box 68305 Nashville, TN 37206
[email protected]
EIN Tax ID: 46-3399632

Join Our Mailing List

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Nikki Mitchell Foundation, PO Box 68305, Nashville, TN, 37206, http://www.nikkimitchellfoundation.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Follow Us

Contact Us

1-615-982-6802
PO Box 68305 Nashville, TN 37206
[email protected]
EIN Tax ID: 46-3399632
Copyright ©2020 Nikki Mitchell Foundation. All Rights Reserved. Nikki Mitchell Foundation is a registered 501(c)(3) non-profit.

Medical Disclaimer:
Information is solely intended as educational purpose only. It is not to be considered as a substitute for professional medical advice. We encourage all visitors to consult directly with their physician. Site visitors should not rely on any information contained for health needs. Instead, all questions should be discussed with professional medical doctors.
SearchPostsLogin
Wednesday, 30, Mar
Music Leader Shannan Hatch Joins Nikki Mitchell Foundation Board
Thursday, 27, Jan
Your Dollars at Work
Monday, 24, Jan
2021 Impact Report
Monday, 22, Nov
2021 Nikki Mitchell Foundation Seed Grant Winner
Thursday, 17, Jun
A Surviving Story
Monday, 24, May
Clinical Trials

Welcome back,